ESC Premium Access

Novel therapeutic targets in hypertrophic cardiomyopathy

Event: ESC CONGRESS 2019
Topic: Hypertrophic Cardiomyopathy
Session type: Advances in Science
Date: 31 August 2019
Time: 11:00 - 12:30


5 presentations in this session

State of the Art in the treatment of hypertrophic cardiomyopathy

Speaker: Professor I. Olivotto (Florence, IT)

Earlier surgical myectomy vs. waiting for a Class I indication is associated with improved long-term survival in symptomatic hypertrophic obstructive cardiomyopathy patients

Speaker: Doctor M. Desai (Cleveland, US)

A novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)

Speaker: Doctor G. Norrish (London, GB)

Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study

Speaker: Professor A. Wang (Durham, US)

Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.

Speaker: Professor J. Veselka (Prague, CZ)

5 speakers from this session

Professor Iacopo Olivotto

Careggi University Hospital (AOUC), Florence (Italy)
11 presentations

Doctor Milind Desai

Cleveland Clinic Foundation, Cleveland (United States of America)
12 presentations
0 follower

Doctor Gabrielle Norrish

University College London, London (United Kingdom of Great Britain & Northern Ireland)
0 follower

Professor Andrew Wang

Duke University Medical Center, Durham (United States of America)
0 follower

Professor Josef Veselka

University Hospital Motol, CardioVascular Center, Prague (Czechia)
2 presentations
0 follower

This platform is supported by

logo Novo Nordisk